VISTAGEN THERAPEUTICS, INC. (VTGN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Win.
19/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseVTGN / S&P -59.65% / 15.20% |
WinVTGN / S&P 287.31% / 15.00% |
LoseVTGN / S&P -7.26% / 50.40% |
| 2026-Q11/3 |
LoseVTGN / S&P -13.64% / -4.33% |
WinVTGN / S&P 161.32% / 11.30% |
LoseVTGN / S&P 9.58% / 27.70% |
| 2025-Q42/3 |
LoseVTGN / S&P -81.41% / 2.65% |
WinVTGN / S&P 13.18% / 9.00% |
WinVTGN / S&P 28.38% / 13.40% |
| 2025-Q32/3 |
WinVTGN / S&P 77.50% / 8.12% |
LoseVTGN / S&P -17.60% / 4.61% |
WinVTGN / S&P 54.03% / 13.45% |
| 2025-Q21/3 |
LoseVTGN / S&P -20.00% / 10.94% |
LoseVTGN / S&P -33.40% / 4.83% |
WinVTGN / S&P 20.95% / 10.63% |
| 2025-Q10/3 |
LoseVTGN / S&P -15.25% / -4.27% |
LoseVTGN / S&P -54.28% / 4.98% |
LoseVTGN / S&P -19.32% / 10.57% |
| 2024-Q40/3 |
LoseVTGN / S&P -1.99% / 2.41% |
LoseVTGN / S&P VTGN unavailable / 5.25% |
LoseVTGN / S&P VTGN unavailable / 6.15% |
| 2024-Q30/3 |
LoseVTGN / S&P -13.51% / 5.89% |
LoseVTGN / S&P VTGN unavailable / 5.89% |
LoseVTGN / S&P VTGN unavailable / 6.11% |
| 2024-Q20/3 |
LoseVTGN / S&P -34.09% / 4.28% |
LoseVTGN / S&P VTGN unavailable / 5.38% |
LoseVTGN / S&P VTGN unavailable / 5.12% |
| 2024-Q10/3 |
LoseVTGN / S&P 2.72% / 10.56% |
LoseVTGN / S&P VTGN unavailable / 5.71% |
LoseVTGN / S&P VTGN unavailable / 5.59% |
| 2023-Q40/3 |
LoseVTGN / S&P -1.91% / 11.69% |
LoseVTGN / S&P VTGN unavailable / 6.81% |
LoseVTGN / S&P VTGN unavailable / 7.78% |
| 2023-Q31/3 |
WinVTGN / S&P 180.21% / -3.27% |
LoseVTGN / S&P VTGN unavailable / 7.52% |
LoseVTGN / S&P VTGN unavailable / -5.03% |
| 2023-Q20/3 |
LoseVTGN / S&P -48.06% / 8.74% |
LoseVTGN / S&P VTGN unavailable / 9.50% |
LoseVTGN / S&P VTGN unavailable / -8.57% |
| 2023-Q11/3 |
WinVTGN / S&P 20.00% / 7.50% |
LoseVTGN / S&P VTGN unavailable / 10.77% |
LoseVTGN / S&P VTGN unavailable / -15.69% |
| 2022-Q40/3 |
LoseVTGN / S&P -33.33% / 7.56% |
LoseVTGN / S&P VTGN unavailable / 11.88% |
LoseVTGN / S&P VTGN unavailable / -17.99% |
| 2022-Q30/3 |
LoseVTGN / S&P -82.95% / -4.88% |
LoseVTGN / S&P VTGN unavailable / 13.47% |
LoseVTGN / S&P VTGN unavailable / -1.41% |
| 2022-Q20/3 |
LoseVTGN / S&P -29.03% / -16.10% |
LoseVTGN / S&P -26.23% / 13.71% |
LoseVTGN / S&P VTGN unavailable / 11.04% |
| 2022-Q10/3 |
LoseVTGN / S&P -36.41% / -4.60% |
LoseVTGN / S&P 1.78% / 15.97% |
LoseVTGN / S&P VTGN unavailable / 42.23% |
| 2021-Q41/3 |
LoseVTGN / S&P -28.83% / 11.03% |
WinVTGN / S&P 133.46% / 15.00% |
LoseVTGN / S&P VTGN unavailable / 96.40% |
| 2021-Q31/3 |
LoseVTGN / S&P -13.02% / 0.58% |
WinVTGN / S&P 339.40% / 10.77% |
LoseVTGN / S&P VTGN unavailable / 69.42% |
| 2021-Q21/3 |
WinVTGN / S&P 47.89% / 8.55% |
LoseVTGN / S&P VTGN unavailable / 6.58% |
LoseVTGN / S&P VTGN unavailable / 51.81% |
| 2021-Q11/3 |
WinVTGN / S&P 9.79% / 6.17% |
LoseVTGN / S&P VTGN unavailable / -1.06% |
LoseVTGN / S&P VTGN unavailable / 7.39% |
| 2020-Q41/3 |
WinVTGN / S&P 177.14% / 12.15% |
LoseVTGN / S&P VTGN unavailable / -3.72% |
LoseVTGN / S&P VTGN unavailable / -33.42% |
| 2020-Q31/3 |
WinVTGN / S&P 32.08% / 8.93% |
LoseVTGN / S&P VTGN unavailable / -2.04% |
LoseVTGN / S&P VTGN unavailable / -27.10% |
| 2020-Q20/3 |
LoseVTGN / S&P 20.45% / 20.54% |
LoseVTGN / S&P VTGN unavailable / -0.46% |
LoseVTGN / S&P VTGN unavailable / -27.11% |
| 2020-Q10/3 |
LoseVTGN / S&P -36.23% / -19.60% |
LoseVTGN / S&P VTGN unavailable / 3.47% |
LoseVTGN / S&P VTGN unavailable / -14.75% |
| 2019-Q40/3 |
LoseVTGN / S&P -35.51% / 9.07% |
LoseVTGN / S&P VTGN unavailable / 5.36% |
LoseVTGN / S&P VTGN unavailable / 2.99% |
| 2019-Q31/3 |
WinVTGN / S&P 46.58% / 1.70% |
LoseVTGN / S&P VTGN unavailable / 5.02% |
LoseVTGN / S&P VTGN unavailable / 0.21% |
| 2019-Q20/3 |
LoseVTGN / S&P -42.97% / 4.30% |
LoseVTGN / S&P VTGN unavailable / 6.64% |
LoseVTGN / S&P VTGN unavailable / 8.65% |
| 2019-Q10/3 |
LoseVTGN / S&P -14.67% / 13.65% |
LoseVTGN / S&P VTGN unavailable / 8.12% |
LoseVTGN / S&P VTGN unavailable / 14.29% |
| 2018-Q41/3 |
WinVTGN / S&P 3.45% / -13.52% |
LoseVTGN / S&P VTGN unavailable / 9.05% |
LoseVTGN / S&P VTGN unavailable / 18.23% |
| 2018-Q30/3 |
LoseVTGN / S&P 5.84% / 7.71% |
LoseVTGN / S&P VTGN unavailable / 10.21% |
LoseVTGN / S&P VTGN unavailable / 19.06% |
| 2018-Q21/3 |
WinVTGN / S&P 47.31% / 3.43% |
LoseVTGN / S&P VTGN unavailable / 9.03% |
LoseVTGN / S&P VTGN unavailable / 14.46% |
| 2018-Q10/3 |
LoseVTGN / S&P -16.22% / -0.76% |
LoseVTGN / S&P VTGN unavailable / 7.68% |
LoseVTGN / S&P VTGN unavailable / 12.46% |
| 2017-Q40/3 |
LoseVTGN / S&P -30.63% / 6.64% |
LoseVTGN / S&P VTGN unavailable / 7.03% |
LoseVTGN / S&P VTGN unavailable / 13.82% |
| 2017-Q30/3 |
LoseVTGN / S&P -14.44% / 4.48% |
LoseVTGN / S&P VTGN unavailable / 5.68% |
LoseVTGN / S&P VTGN unavailable / 17.57% |
| 2017-Q20/3 |
LoseVTGN / S&P -4.59% / 3.09% |
LoseVTGN / S&P VTGN unavailable / 4.83% |
LoseVTGN / S&P VTGN unavailable / 17.74% |
| 2017-Q10/3 |
LoseVTGN / S&P -47.45% / 6.07% |
LoseVTGN / S&P VTGN unavailable / 3.67% |
LoseVTGN / S&P VTGN unavailable / 13.32% |
| 2016-Q40/3 |
LoseVTGN / S&P -11.82% / 3.82% |
LoseVTGN / S&P VTGN unavailable / 2.09% |
LoseVTGN / S&P VTGN unavailable / 7.05% |
| 2016-Q31/3 |
WinVTGN / S&P 8.46% / 3.85% |
LoseVTGN / S&P VTGN unavailable / 0.20% |
LoseVTGN / S&P VTGN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VTGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -92.22% | 20.78% |
| Annualized return | -92.22% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VTGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.72% | 83.14% |
| Annualized return | -69.07% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | VTGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.76% | 319.30% |
| Annualized return | -45.31% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |